Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | IFNAR1 | P17181 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16066023 | 0.83 | SLC6A4 (0.40) | SLC6A4SLC6A2SLC6A3LTA4HALDH1A1 | |
| SCHEMBL24246243 | 0.83 | ALDH1A1 (0.41) | ALDH1A1KDM4ETSHRTDP1GAA | |
| SCHEMBL19300835 | 0.82 | SLC6A4 (0.39) | SLC6A4SLC6A2SLC6A3LTA4HALDH1A1 | |
| SCHEMBL5435016 | 0.81 | ALDH1A1 (0.48) | ALDH1A1KDM4ETSHRTDP1GAA | |
| SCHEMBL514804 | 0.81 | IDO1 (0.50) | SLC6A4SLC6A2SLC6A3ALDH1A1KDM4E | |
| SCHEMBL13552274 | 0.81 | MAPT (0.44) | ALDH1A1KDM4ETSHRTDP1MAPT | |
| SCHEMBL24938827 | 0.79 | GAA (0.44) | SLC6A4SLC6A2SLC6A3ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL25377091 | 0.79 | IDO1 (0.52) | SLC6A4SLC6A2SLC6A3ALDH1A1KDM4E | |
| SCHEMBL2909758 | 0.79 | TAAR1 (0.55) | SLC6A2ALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL31265560 | 0.78 | SLC6A4 (0.57) | SLC6A4SLC6A2SLC6A3LTA4HALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023125737-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | SILEXON AI TECHNOLOGY CO., LTD. (CN) | 2023-07-06 | — | — | WO | disclosed |
| US-10316022-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-9988386-B2 | Compounds for treatment of diseases of abnormal angiogenesis or aberrant growth factors and uses thereof | Kata Pharmaceuticals, Inc. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20180037573-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2018-02-08 | — | — | US | disclosed |
| US-20180037572-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2018-02-08 | — | — | US | disclosed |
| US-9802922-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802922-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9790228-B2 | Heterocyclic kinase inhibitors | INTELLIKINE LLC (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170246310-A1 | VAR2CSA-DRUG CONJUGATES | ZYMEWORKS INC. (CA) | 2017-08-31 | — | — | US | disclosed |
| US-20170129876-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2017-05-11 | — | — | US | disclosed |
| US-20160137646-A1 | Novel Compounds and Uses Thereof | KALA PHARMACEUTICALS, INC. (US) | 2016-05-19 | — | — | US | disclosed |
| US-20160060264-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2016-03-03 | — | — | US | disclosed |
| US-20160060264-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2016-03-03 | — | — | US | disclosed |
| US-9212145-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212145-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| WO-2015095953-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2015-07-02 | — | — | WO | disclosed |
| US-20150072986-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2015-03-12 | — | — | US | disclosed |
| US-20150072986-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2015-03-12 | — | — | US | disclosed |
| US-20110281866-A1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20100197657-A1 | 2-ARYL OR HETEROARYL INDOLE DERIVATIVES | CHANG RONALD K | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072986-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | SLC6A4 4289/4885SLC6A2 4308/4885SLC6A3 3234/4885 |
| US-20100197657-A1 | 2-ARYL OR HETEROARYL INDOLE DERIVATIVES | ASIC1, ASIC3, TRPV1 | SLC6A4 311/4885SLC6A2 316/4885SLC6A3 397/4885 |
| US-20170246310-A1 | VAR2CSA-DRUG CONJUGATES | VARS1, GUSB, VAV1 | SLC6A4 1100/4885SLC6A2 188/4885SLC6A3 261/4885 |
| US-20160137646-A1 | Novel Compounds and Uses Thereof | RB1, VEGFA, UACA | SLC6A4 3552/4885SLC6A2 4335/4885SLC6A3 3579/4885 |
| US-10316022-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | SLC6A4 4289/4885SLC6A2 4308/4885SLC6A3 3234/4885 |
| US-20180037572-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | SLC6A4 4289/4885SLC6A2 4308/4885SLC6A3 3234/4885 |
| US-20180037573-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | SLC6A4 4289/4885SLC6A2 4308/4885SLC6A3 3234/4885 |
| US-20110281866-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K13, MAP3K3, CDK3 | SLC6A4 4847/4885SLC6A2 4880/4885SLC6A3 4579/4885 |
| US-20170129876-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | SLC6A4 4289/4885SLC6A2 4308/4885SLC6A3 3234/4885 |
| US-20160060264-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | SLC6A4 4289/4885SLC6A2 4308/4885SLC6A3 3234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.